Vrd.co

LONDON–(BUSINESS WIRE[1])–The global virtual retinal display (VRD) market[2] is expected to grow at a CAGR of 3.51% during the forecast period, according to Technavio’s latest report. In this report, Technavio[3] covers the market outlook and growth prospects of the global VRD[4] market for 2016-2020. To calculate the market size, the report considers revenue generated from shipment of VRD devices for...

For media and investors only Issued: London, UK EDITOR’S NOTE: This press release has been updated to reflect a median overall survival of 13.7 months instead of 14.9 months based on a re-analysis of the DREAMM-2 study following the identification of a discrepancy in patient data used to calculate overall survival estimates. (Updated as of 30/06/2020) 13-month update on the...

Issued: London UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916). The 196 patients in the trial had relapsed multiple myeloma, were refractory to an immunomodulatory drug, a proteasome inhibitor, and to treatment with an anti-CD38 antibody. The two-arm study met its primary objective and...